Conference

Pre ICPR Events

About

Conference

Pre ICPR Events

About

Pathways to Access Summit (Paths)

Psychedelic Therapeutics in Europe and Beyond


5 June, 2024 | Philharmonie, Haarlem | The Netherlands

Add-on event the day before ICPR 2024

Add-on event the day before ICPR 2024

Pathways to Access Summit (Paths)

Psychedelic Therapeutics in Europe and Beyond


5 June, 2024 | Philharmonie, Haarlem | The Netherlands

Add-on event the day before ICPR 2024

Add-on event the day before ICPR 2024

Pathways to Access Summit (Paths)

Psychedelic Therapeutics in Europe and Beyond


5 June, 2024 | Philharmonie, Haarlem | The Netherlands

Add-on event the day before ICPR 2024

Add-on event the day before ICPR 2024


Co-organised by

Co-organised by

A Full Day of Insightful Exploration

A Full Day of Insightful Exploration

A Full Day of Insightful Exploration

With the FDA likely approving MDMA-assisted therapy as a treatment for PTSD later this year in the United States, and the evidence supporting the potential of psychedelic therapies further accumulating, 2024 is shaping up to be a pivotal year for the therapeutic use of psychedelics. However, the path to approval and - crucially - patient access in Europe remains uncertain. 


The full-day Pathways to Access Summit (Paths) convenes key stakeholders from Europe and beyond to explore the opportunities and challenges around the development, approval, and eventual integration of psychedelic medicines into mainstream European health care.


This summit will unravel the complexities of European regulatory frameworks, addressing the diverse and ever-changing healthcare systems, assessments for pricing and reimbursement, and unique regulatory challenges. We will identify which stakeholders to engage with at each stage of the journey from bench to bedside and share best practices for doing so. We will discuss how to effectively navigate the European regulatory landscape, incorporating insights from other regulatory systems, and offer a well-rounded perspective on the different approaches and best practices to psychedelic medicine regulation.


With growing interest in the potential of psychedelic therapies for mental disorders, understanding the regulatory frameworks and pathways to access of these treatments is now more pertinent than ever.


At the full-day Pathways to Access Summit (PATHS), we will explore what the integration of psychedelic medicines into mainstream European mental health services will entail. During this interactive event, we will delve into the evolving pathways for accessing these innovative treatments, and focusing on safe, timely, and ethical implementation. We will unravel the complexities of European regulatory frameworks, addressing all different stages: from clinical research to reimbursable treatments, which stakeholders to involve in what phase, and how to navigate this process efficiently. 


PATHS is a stand-alone event leading up to ICPR, which builds on the insights of the 2022 Psychedelic Science, Ethics & Business Symposium.

With the FDA likely approving MDMA-assisted therapy as a treatment for PTSD later this year in the United States, and the evidence supporting the potential of psychedelic therapies further accumulating, 2024 is shaping up to be a pivotal year for the therapeutic use of psychedelics. However, the path to approval and - crucially - patient access in Europe remains uncertain. 


The full-day Pathways to Access Summit (Paths) convenes key stakeholders from Europe and beyond to explore the opportunities and challenges around the development, approval, and eventual integration of psychedelic medicines into mainstream European health care.


This summit will unravel the complexities of European regulatory frameworks, addressing the diverse and ever-changing healthcare systems, assessments for pricing and reimbursement, and unique regulatory challenges. We will identify which stakeholders to engage with at each stage of the journey from bench to bedside and share best practices for doing so. We will discuss how to effectively navigate the European regulatory landscape, incorporating insights from other regulatory systems, and offer a well-rounded perspective on the different approaches and best practices to psychedelic medicine regulation.


Key Questions to be Addressed

Key Questions to be Addressed

Key Questions to be Addressed

With participation from key stakeholders, EU institutions and global experts, this summit will focus on the following questions:

With participation from key stakeholders, EU institutions and global experts, this summit will focus on the following questions:

With participation from key stakeholders, EU institutions and global experts, this summit will focus on the following questions:

  • What are the prevalent compliance and availability challenges several nations are presently wrestling with?

  • What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?

  • Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?

  • What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?

  • What are the prevalent compliance and availability challenges several nations are presently wrestling with?

  • What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?

  • Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?

  • What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?

  • What are the prevalent compliance and availability challenges several nations are presently wrestling with?

  • What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?

  • Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?

  • What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?


Why Attend Paths?


Why Attend Paths?


Why Attend Paths?

This interactive summit will feature plenary presentations, panel discussions, group discussions, side events, and more; enabling attendees to engage in detailed conversations on EU regulatory policies, examine legal access routes, receive unique insights and access to insiders in the regulatory, policy, science, and industry fields.


This interactive summit will feature plenary presentations, panel discussions, group discussions, side events, and more; enabling attendees to engage in detailed conversations on EU regulatory policies, examine legal access routes, receive unique insights and access to insiders in the regulatory, policy, science, and industry fields.


This interactive summit will feature plenary presentations, panel discussions, group discussions, side events, and more; enabling attendees to engage in detailed conversations on EU regulatory policies, examine legal access routes, receive unique insights and access to insiders in the regulatory, policy, science, and industry fields.


Learn & Strategize

Learn & Strategize

Learn & Strategize

Understand the complex and challenging journey of integrating novel treatments into the European healthcare system, with the regulatory, clinical, and economic hurdles encountered along the way.

Network & Collaborate

Network & Collaborate

Network & Collaborate

Build a strong network among academia, regulators, patients, and industry.


Who is Paths for?


Who is Paths for?


Who is Paths for?

This one-day summit is essential for those invested in the future of psychedelic medicines.

This one-day summit is essential for those invested in the future of psychedelic medicines.

This one-day summit is essential for those invested in the future of psychedelic medicines.

Academia

Academia

Academia

* Clinical scientists / CRO's

* Researchers

* Students


* Clinical scientists / CRO's

* Researchers

* Students


* Clinical scientists / CRO's

* Researchers

* Students


Politics & Society

Politics & Society

Politics & Society

* Policymakers / Regulators

* Healthcare professionals

* Psychedelic industry professionals

* Patients

* Policymakers / Regulators

* Healthcare professionals

* Psychedelic industry professionals

* Patients

* Policymakers / Regulators

* Healthcare professionals

* Psychedelic industry professionals

* Patients

Business

Business

Business

* Investors

* Insurers

* Executives

* Investors

* Insurers

* Executives

* Investors

* Insurers

* Executives


Practicalities


Practicalities

Practicalities

Date

Date

Date

5th of June, 2024
The day before ICPR 2024


5th of June, 2024
The day before ICPR 2024


5th of June, 2024
The day before ICPR 2024


Location

Location

Location

Philharmonie, Haarlem
The Netherlands
Same location as ICPR 2024

Philharmonie, Haarlem
The Netherlands
Same location as ICPR 2024

Philharmonie, Haarlem
The Netherlands
Same location as ICPR 2024

Questions

Questions

Questions

Ticketing Options

Ticketing Options

Tickets

Paths Regular Ticket

€299

In-Person Ticket for Attendees

Includes on-site access to the Pathways to Access Summit on Wednesday.

Full Venue and Programme Access PLUS:

  • Meet and Network with 300+ Attendees

  • Badging: Name, Title, Org

  • Regular OPEN Membership

  • Access All Recorded Content

Food, Beverages

Coffee, tea, fruits, snacks, water, plus a healthy vegetarian, mainly organic lunch!

ICPR + Paths Package Deals

ICPR + Paths Package Deals

Professional Package

€1199

Includes:

  • ICPR Professional Ticket

  • PATHS Regular Ticket

Standard Package

€849

Includes:

  • ICPR Regular Ticket

  • PATHS Regular Ticket

Student Package

€529

Includes:

  • ICPR Student Ticket

  • PATHS Regular Ticket

© 2007-2024 ICPR by OPEN Foundation, Amsterdam, the Netherlands
© 2007-2024 ICPR by OPEN Foundation, Amsterdam, the Netherlands
© 2007-2024 ICPR by OPEN Foundation, Amsterdam, the Netherlands